Format

Send to

Choose Destination
Hepatology. 2016 Nov;64(5):1442-1450. doi: 10.1002/hep.28571. Epub 2016 Jun 1.

Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.

Author information

1
Massachusetts General Hospital Institute for Technology Assessment, Boston, MA.
2
Harvard Medical School, Boston, MA.
3
Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA.
4
H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology, Atlanta, GA.
5
Department of Industrial and Systems Engineering, University of Florida, Gainesville, FL.
6
Department of Health Policy and Management, University of Pittsburgh, Pittsburgh, PA.
7
Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center.
8
Department of Medicine, Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX USA.
#
Contributed equally

Abstract

Oral direct-acting antivirals (DAAs) represent a major advance in hepatitis C virus (HCV) treatment. Along with recent updates in HCV screening policy and expansions in insurance coverage, treatment demand in the United States is changing rapidly. Our objective was to project the characteristics and number of people needing antiviral treatment and HCV-associated disease burden in the era of oral DAAs. We used a previously developed and validated Hepatitis C Disease Burden Simulation model (HEP-SIM). HEP-SIM simulated the actual clinical management of HCV from 2001 onward, which included antiviral treatment with pegylated interferon (Peg-IFN)-based therapies as well as the recent oral DAAs, risk-based and birth-cohort HCV screening, and the impact of the Affordable Care Act. We also simulated two hypothetical scenarios-no treatment and treatment with Peg-IFN-based therapies only. We estimated that in 2010, 2.5 (95% confidence interval [CI], 1.9-3.1) million noninstitutionalized people were viremic, which dropped to 1.9 (95% CI, 1.4-2.6) million in 2015, and projected to drop below 1 million by 2020. A total of 1.8 million HCV patients will receive HCV treatment from the launch of oral DAAs in 2014 until 2030. Based on current HCV management practices, it will take 4-6 years to treat the majority of patients aware of their disease. However, 560,000 patients would still remain unaware by 2020. Even in the oral DAA era, 320,000 patients will die, 157,000 will develop hepatocellular carcinoma, and 203,000 will develop decompensated cirrhosis in the next 35 years.

CONCLUSIONS:

HCV-associated disease burden will still remain substantial in the era of oral DAAs. Increasing HCV screening and treatment capacity is essential to further decreasing HCV burden in the United States. (Hepatology 2016;64:1442-1450).

Comment in

PMID:
27015107
PMCID:
PMC5035714
DOI:
10.1002/hep.28571
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center